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Available online xxxxWehave successfully used comparative genomics to identify putative regulatory elementswithin the human ge-
nome that contribute to the tissue speciﬁc expression of neuropeptides such as galanin and receptors such as CB1.
However, a previous inability to rapidly delete these elements from the mouse genome has prevented optimal
assessment of their function in-vivo. This has been solved using CAS9/CRISPR genome editing technology
which uses a bacterial endonuclease called CAS9 that, in combination with speciﬁcally designed guide RNA
(gRNA) molecules, cuts speciﬁc regions of the mouse genome. However, reports of “off target” effects, whereby
the CAS9 endonuclease is able to cut sites other than those targeted, limits the appeal of this technology.Weused
cytoplasmic microinjection of gRNA and CAS9 mRNA into 1-cell mouse embryos to rapidly generate enhancer
knockout mouse lines. The current study describes our analysis of the genomes of these enhancer knockout
lines to detect possible off-target effects. Bioinformatic analysis was used to identify the most likely putative
off-target sites and to design PCR primers that would amplify these sequences from genomic DNA of founder en-
hancer deletion mouse lines. Ampliﬁed DNA was then sequenced and blasted against the mouse genome se-
quence to detect off-target effects. Using this approach we were unable to detect any evidence of off-target
effects in the genomes of three founder lines using any of the four gRNAs used in the analysis. This study suggests
that the problem of off-target effects in transgenicmice have been exaggerated and that CAS9/CRISPR represents
a highly effective and accurate method of deleting putative neuropeptide gene enhancer sequences from the
mouse genome.
© 2016 Published by Elsevier Ltd.Keywords:
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Neuropeptides and their receptors play a crucial role in maintaining
the homeostasis of the human nervous system and in maintaining
health (Freimann et al., 2015; Davidson et al., 2011). Neuropeptides
such as galanin play critical roles in inﬂammation (Pinter et al., 2013),
mood, appetite and alcohol intake and their mis-expression has been
associated with inﬂammatory pain, depression, alcohol abuse and obe-
sity (Lang et al., 2015). Tightly controlled cell and tissue speciﬁc expres-
sion of neuropeptides is critical to their function and there is evidence
that mis-regulation of neuropeptides and/or their receptors is associat-
ed with disease progression (Shanley et al., 2010, 2011). In order to un-
derstand the genomic mechanisms that control the expression of the
gene that encodes galanin we have previously used comparative geno-
mics to identify candidate regulatory regions within and around the
galanin gene (GAL) locus (Davidson et al., 2011).We were able to iden-
tify a 1.5 kilobase (kb) region 42 kbupstream from the humanGAL locus
that we called GAL5.1. We cloned this sequence and made reporternalysis of possible off target e
(2016), http://dx.doi.org/10constructs which were then used to generate reporter mouse lines,
using pronuclear microinjection, that expressed the β-galactosidase re-
porter gene in precisely the same cells that expressed GAL mRNA and
galanin peptide (Davidson et al., 2011). Moreover, we were able to re-
port signiﬁcant differences in the activities of polymorphic variants of
GAL5.1 in primary hypothalamic neurones (Davidson et al., 2011). The
next logical step in the study of GAL5.1would have involved its deletion
from themouse genome to permit study of the effects of its deletion on
the expression of theGAL locus aswell as appetite,mood, the inﬂamma-
tory response and alcohol intake. However, the expense and time re-
quired to delete GAL5.1 from the mouse genome using existing
embryonic stem cell targeting based technologies precluded this
approach.
The last three years have seen the development of a new technology
called CAS9/CRISPR genome editing that promises to revolutionise in-
vivo biology (Singh et al., 2014). Brieﬂy, CAS9/CRISPR genome editing
relies on the ability of the bacterial CAS9 protein to induce a double
strand cut in any region of the genome identiﬁed by a guide RNA
(gRNA) molecule. The CAS9 protein forms a complex with the gRNA
molecule which then ascribes sequence speciﬁcity on the CAS9 protein.
In this way, any sequence within the genome of any species can beffects following CAS9/CRISPR targeted deletions of neuropeptide gene
.1016/j.npep.2016.11.003
Table 1
Guide sequence selections (PAM sequence in bold) and genomic coordinates targeted in
mouse genome.
Target
region Guide sequences
Genomic coordinates
targeted (GRCm38/mm10)
GAL5.1a Guide 4: ATGGCTCCCAACAATGCGCCAGG
(AGG)
chr19:3,441,174–3,441,196
Guide 8: CGTCAGAGGCCCGTGACTAACGG
(CGG)
chr19:3,441,324–3,441,349
ECR1 Guide 11: GTCAGAACACTACTGTGTAC
(AGG)
chr4:33,937,559–33,937,601
Guide 13: GTTCATTTGCAATGTAGCTT
(AGG)
chr4:33,937,414–33,937,456
Table 2
PCR primers used to detect correct targeting events.
Targeted locus Deletion detection primers
ΔGAL5.1 AGTTAGGGCGCACACATCAA
CCGTGACTAACGGCTAATGC
ΔECR1 TGTGTGCAGAGAGGGGAGAC
CTTTAGGAGTGGACAAGGGGTC
2 E.A. Hay et al. / Neuropeptides xxx (2016) xxx–xxxtargeted provided that the recognition sequence of the gRNA is next to a
short 3 base pair PAM (protospacer adjacent motif = NGG) and the
CAS9/gRNA complex can be introduced into the cell. However, reports
questioning the speciﬁcity of the CAS9-gRNA complex have raised
fears of the cutting of “off-target” sites by the CAS9/CRISPR system
where CAS9-gRNA complexes are able to cut non-target sites that differ
from the actual target site by 1–5 base pairs (Fu et al., 2013; Mali et al.,
2013). Although the cutting of these off-target sites are orders ofmagni-
tude rarer than “on-target” sites nevertheless this phenomenon has
raised concerns of the use of CRISPR/CAS9 technologies (Zhang et al.,
2015; Peng et al., 2015) although recent studies have gone some way
to addressing these fears (Shen et al., 2014). A number of different ap-
proaches have been used to address the generation of off-target effects
mostly involving the production of mutant “nickase” versions of the
CAS9 enzyme (Ran et al., 2013) or by generation of versions of CAS9
with reduced off-target selection (Slaymaker et al., 2016). Because
RNA is rapidly degraded in cells we explored the possibility that injec-
tion of CAS9 mRNA and sgRNA into the cytoplasm of one-cell mouse
embryos would reduce or alleviate the introduction of “off target ef-
fects” in resulting mouse lines. Thus, instead of microinjecting CAS9
and gRNA expressing plasmids into the pronucleus of 1-cell mouse em-
bryos we chose to introduce gRNA and CAS9 mRNA by their injection
into the cytoplasm of 1-cell embryos to minimise the exposure of the
genome to CAS9 activity (Horii et al., 2014). To test this approach weTable 3
Most likely off-target sites predicted across the mouse genome for guides in Table 1. The “mism
their position (in square brackets) within the predicted off-target sequence when compared to
Off-target sequence
Guide 4 1.CTGGCTCCCAAAAATGTGCCTGG
2.TTTCCTCCCAACAATGAGCCTAG
3.AAGGCTCACTACAATGTGCCAAG
4.TTGGAAGCCAACAATGCGCCAAG
Guide 8 1.AGCTAGAGGCCTGTGACTAATAG
2.AATCAGTGTCCCGTGACTAAAGG
3.AGGCAGAGGACCGTGAGTAAAGG
4.GGTAAGTGGCCCATGACTAAGGG
Guide 11 1.ATCTCCATGGAAAAATAAGGCAG
2.CTCCTCATGCAAAAATAAGGAAG
3.CTCTCAATGGAAAAATAAGGGAG
4.GTATCCAGCCAAAAATAAGGTAG
Guide 13 1.GTTTTTTTGCAATGTAGCTTTAG
2.ATTCTTTGGAAATGTAGCTTGAG
3.TTTCATTTGAAGTGTAGCTTAAG
4.CTTCTTTTGGCATGTAGCTTCAG
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mRNA co-injected with two gRNA molecules ﬂanking the GAL5.1
locus and examined the genomes of these founder lines using a combi-
nation of PCR, Sanger sequencing and bioinformatics.2. Materials and methods
2.1. Generation of gRNA molecules
gRNAmolecules were designed to target the most conserved region
within the GAL5.1 and ECR1 enhancers using the optimised CRISPR de-
sign tool (http://CRISPR.mit.edu/)(Table 1). These guide sequences
were used to make T7 templates as described (Harms et al., 2014) and
were transcribed to using a Megashortscript T7 in-vitro transcription
kit (Ambion) to produce gRNAs as described in the manufacturer's in-
structions with modiﬁcations by Harms et al. (2014).2.2. Production of genome edited mice
gRNAmoleculesweremicroinjected at a concentration 10 ng/μl each
into the cytoplasmof 1-cell C57/BL6 embryos as described (Harms et al.,
2014) togetherwith 10 ng/μl CAS9mRNA (Life Technologies). Surviving
two-cell embryos were introduced into host CD1mothers using oviduct
transfer as previously described (Nagy et al., 2003). Once weaned sur-
viving pups ear-clip biopsies were recovered from these animals and
stored frozen for further analysis.2.3. DNA extraction
600 μl of 50mMNaOHwas added to each ear-clip biopsy sample and
tubes heated at 95 °C for 10 min. After vortexing the solution was
neutralised with 50 μl of 1 M Tris HCl (pH 8) and spun at 13,000 rpm
for 5 min. The topmost 400 μl was then extracted for subsequent PCR
analysis. Correctly deleted loci were detected by PCR using the oligonu-
cleotide pairs shown in Table 2.2.4. Prediction of off-target sites
The CRISPR design tool (http://CRISPR.mit.edu/) also permitted the
prediction of likely off-target sites within the rest of themouse genome
based on the sequence of each of the gRNA recognition sequences cho-
sen. We chose putative off-target sequences around themouse genome
that contained the minimal numbers of mis-match regions and which
therefore representing the most likely off-target cut sites (Table 3).atch” column displays howmany mismatches (MM) the program detected (2-4MM) and
the target sequence.
Mismatches (MM) Genomic coordinates (GRCm38/mm10)
3MMs[1:12:17] chr15:4,531,305–4,531,327
4MMs[1:3:4:17] chr15:34,336,397–34,336,419
4MMs[2:8:10:17] chrX:58,284,910–58,284,932
4MMs[1:5:6:7] chr17:27,845,339–27,845,361
4MMs[1:3:4:12] chr4:36,468,479–36,468,501
4MMs [1:2:7:9] chr11:35,124,332–35,124,354
4MMs[1:3:10:17] chr4:109,793,697–109,793,719
4MMs [1:4:7:13] chr7:139,558,969–139,558,991
2MMs[1:10] chr4:7,893,773–7,893,795
2MMs[4:5] chr14:98,049,760–98,049,782
2MMs[6:10] chr6:46,598,551–46,598,573
4MMs[1:3:8:9] chr4:154,290,932–154,290,954
2MMs[4:5] chr12:38,313,780–38,313,802
4MMs[1:5:8:10] chr8:49,053,837–49,053,859
3MMs[1:10:12] chr6:5,207,740–5,207,762
4MMs[1:5:10:11] chr6:24,449,864–24,449,886
ffects following CAS9/CRISPR targeted deletions of neuropeptide gene
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Fig. 1. PCR analysis of earclip DNA derived from CRISPR genome editedmice using primer
pairs shown in Table 2 demonstrating successful deletion of target loci. Mice were
generated using the guide sequences in Table 1 and the change in the sizes of the PCR
product reﬂects successful deletion of the targeted locus using the guide RNAs shown in
Table 1. Hom, Homozygous deletion at both loci; Het, Heterozygous deletion at only one
locus; WT, wild type loci. 100 bp, 100 base pair ladder marker.
3E.A. Hay et al. / Neuropeptides xxx (2016) xxx–xxx2.5. Identiﬁcation of ﬂanking regions of putative off-target sites and primer
design
Putative off-target sites, as predicted by the CRISPR design tool (http://
CRISPR.mit.edu/) were blasted against the mouse genome using the
UCSC-genome browser BLAT tool (https://genome.ucsc.edu/cgi-bin/
hgBlat). 500 base pair sequences centred on each predicted off-target site
were downloaded and entered into the NCBI primer design program
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/) to identify optimal
primers to aid ampliﬁcation of PCR products for subsequent sequencing.
PCR primerswere designed that ﬂanked putative off-target sites at an opti-
mal distance of 100–150 base pairs to give PCR product lengths of between
200–300 base pairs in order to aid in subsequent sequencing (Table 4).
2.6. PCR analysis
Test gradient PCR reactions were undertaken on each primer pair
(Euroﬁns) using wild type DNA to optimise their annealing tempera-
tures. Earclip DNA from each founder line was then used as a template
to amplify regions of DNA centred on putative off-target sites using a
GoTaq polymerase mix according to manufacturer's instructions
(Promega). AmpliﬁedDNAwas then puriﬁed using Qiaquick PCR puriﬁ-
cation kit (Qiagen) and adjusted to 80 ng/μl−1. PCR products were
analysed using 1% agarose gel electrophoresis.
2.7. Sequencing
Puriﬁed PCR products were sequenced by GATC-Biotech sequencing
services using each of the PCR primers used for the PCR reaction (See
Table 3).Table 4
Primer sets used to amplify predicted off-target sites in the genomes of founder strains of
ΔECR1 andΔGAL5.1 CAS9/CRISPR targetedmice. The annealing temperature of each oligo-
nucleotide and the predicted amplicon length are also shown.
Off-target
sequence
Primers
(5′-3′)
Annealing
temperature
(°C)
PCR
product
size
(bp)
#4/1 Forward: TCCTACTCTCACAGGGGAGTC 58.3 284
Reverse: GAATGCTTCTCCCAGGGCAT 63.7
#4/2 Forward: TGGAAGTCCCTCTCCTTGGG 63.8 292
Reverse: CAGGGTCTCAGGACAACACC 60.6
#4/3 Forward: GGGCACCCTTTCTGTCTGTA 60.1 456
Reverse: TCTTGCAGGGCTCAGAATGTT 62.2
#4/4 Forward: AAGATCCCTCCTGCTCCGTTC 64.1 232
Reverse:CACAACAGAGGAAATTATGCGGTT 63.4
#8/1 Forward: TCTTTGATCCAGCAGAGGCT 60.1 235
Reverse: TCCTGTAACTGCCCCTCAGT 59.7
#8/2 Forward: AGCATTCCTATCCCTCGTCC 60.4 223
Reverse: AGTTTCACCAGTGGGGATCAG 61.3
#8/3 Forward: GTGCTTCTTGTTGAGCAGCC 61.1 341
Reverse: CTATCTTGCTGGGTGGAGGC 62.1
#8/4 Forward: TGATCTCCTTCCCGTCCCAT 64.0 283
Reverse: TGCCCTGTACAACCCCATTC 63.0
#11/1 Forward: CTGGCTATGCTTTTGGTTGATGTT 63.6 305
Reverse: AAAGATGTTGGGTGTGAATTGAA 60.6
#11/2 Forward: ATGAGGCCAGGAGCCAGATTA 63.2 207
Reverse: AATTACTTCACCCTCGTGGTCC 61.5
#11/3 Forward: GTCCAGAGAGGAGCATTGGG 62.1 316
Reverse: AGGCTGCAGTTAGTGTTGTCA 58.6
#11/4 Forward: CCCGGCAAGGCTCAGTAATA 62.4 230
Reverse: CAGTAGCAAGGGGGACTCAG 59.9
#13/1 Forward:ACCTCTTTCTAGTTCTTCAAATGGA 58.9 254
Reverse: GTCAGAAAGTCGAACAATCTGTG 58.9
#13/2 Forward: CCAAAGAGGTCAGGCTGTGT 60.3 215
Reverse: ATCAGAACTTACGCCACCCT 58.7
#13/3 Forward: GAGGCTACTTCCTGTGGCAT 59.3 240
Reverse: GGAAGGAAGGCCCTAGACAC 60.1
#13/4 Forward: AATGCAGTTCCAGGGAGACC 61.4 267
Reverse: GTCTGATGAATGCTGCACCC 61.7
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services was blasted against the mouse genome using the UCSC-
browser BLAST tool (https://genome.ucsc.edu/cgi-bin/hgBlat) (See
Figs. 1 and 2).
3. Results
3.1. Generation of gRNA
gRNA targeting the GAL5.1 and the ECR1 enhancers was generated
using the CRISPR designed tool as described above and two guides
ﬂanking the most conserved region of both enhancers were chosen
(Table 1).
3.2. Generation of GAL5.1 and ECR1 targeted mice
Five four-week old female C57/BL6 mice were superovulated and
mated to C57/BL6 studs to provide 100–120 one-cell embryos. N90%
survival was obtained after cytoplasmic injection of our gRNA/
CAS9mRNA mixture and surviving two-cell embryos were trans-
ferred into host female mice. In the case of attempts to delete the
GAL5.1 enhancer out of 10 pups that were born we were able to de-
tect two animals that contained the desired deletion for the GAL5.1
enhancer (one heterozygote and one homozygote deletion see
Fig. 1A). Crossing of these lines produced Mendelian proportions of
heterozygotes and homozygote offspring ruling out the possibility
of chimerism in the founder stock. In the case of the ECR1 enhancer
we also successfully generated a number of homozygous ECR1
knockout animals( Fig. 1B)). These animals were referred to as
ΔGAL5.1 andΔECR1 respectively. Earclip DNA from a random sample
of these founder animals was used in subsequent PCR analysis to
detect the possibility of off-target effects.
3.3. Ampliﬁcation of predicted off-target sites
Based on the numbers of mis-matches to the target sequences for
each gRNA as calculated by the CRISPR design tool (http://CRISPR.
mit.edu/) we chose the four most likely off-target sites predicted
for each of the four gRNA molecules using the optimised CRISPRffects following CAS9/CRISPR targeted deletions of neuropeptide gene
.1016/j.npep.2016.11.003
4 E.A. Hay et al. / Neuropeptides xxx (2016) xxx–xxxdesign tool(Table 3). We reasoned that regions of the genome most
similar to the target sequence would represent the most likely off-
target sequences. We blasted these sequences against the UCSC
browser and used 500 base pair genome sequences centred on the
predicted off-target sites to design PCR primers. PCR reactions di-
rected to amplify these sites were optimised using gradient PCR
and PCR products containing the top four most likely off-target
sites, as predicted by the CRISPR design tool, were successfully gen-
erated (Table 4). Together with their respective sequencing primers
these PCR products were sent to GATC-Biotech sequencing services
(https://www.gatc-biotech.com/en/index.html) who were able to
provide high quality sequence data for further analysis.Fig. 2.A-M, UCSC genome browser BLAT comparisons (https://genome.ucsc.edu/cgi-bin/hgBlat
DNA of heterozygous (A-F) andhomozygous (G-M)ΔGAL5.1 founder lines compared to the seq
CRISPR design tool (http://CRISPR.mit.edu/) (Table 2). Differences in sequence are highlighted b
off-target site along the chromosome is designated numerically above each comparison togethe
G, I, J and M as short black bars to highlight possible confounding sequence changes. Exonic se
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Sequences generated by sequencing of PCR products ampliﬁed from
earclip DNA from each of our three founder mouse lines were blasted
against the mouse genome (GRCm38/mm10) using the Blat tool in the
UCSC browser. The results of these blast analyses are shown in Figs. 1
(ΔGAL5.1) and 2 (ΔECR1). Despite the fact that many of the predicted
off-target sites contained as few as two mis-matches (Table 2, Guide
11.1 and 11.2 and guide 13.1) none of the sequences ampliﬁed from
the earclip DNA of any of the three founder lines contained any evidence
of CAS9mediated deletions or base pair changes in any of the four most
likely predicted off-target sites (Figs. 2 and 3).) of sequencing data (long top black bar) derived from PCR products ampliﬁed from earclip
uence of the predicted off-target site (medium length bottomblack bar) as predicted by the
y the presence of a white letter A, T, C, G or Nwithin either black line. The position of each
rwith the DNA sequence. Single polynucleotide polymorphism loci are indicated in A, C, F,
quences are displayed as grey bars in F and M. Scale bars = 10 base pairs.
ffects following CAS9/CRISPR targeted deletions of neuropeptide gene
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Fig. 3.A–H, UCSC genome browser BLAT comparisons (https://genome.ucsc.edu/cgi-bin/hgBlat) of sequencing data (long top black bar) derived from PCR products ampliﬁed from earclip DNA of a homozygousΔECR1 foundermouse compared to the
sequence of the predicted off-target site (medium length bottom black bar) as predicted by the CRISPR design tool (http://CRISPR.mit.edu/) (Table 2).Differences in sequence are highlighted by the presence of awhite letter A, T, C, G or Nwithin either
black line. The position of each off-target site along the chromosome is designated numerically above each comparison together with the DNA sequence. Single polynucleotide polymorphism loci are indicated in A, B, C, E, and H as short black bars to
highlight possible confounding sequence changes. Exonic sequences are displayed as grey bars in D and H. Scale bars = 10 base pairs.
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We have used microinjection of gRNA and CAS9 mRNA molecules
into the cytoplasms of 1-cell mouse embryos to successfully delete
two highly conserved gene enhancer regions (GAL5.1 and ECR1) from
the mouse genome. In order to address concerns about the possibility
of the CAS9 and gRNA system generating “off-target” changes to the
mouse genome we analysed the genomes of three of our founder
mouse lines (one heterozygous, one homozygous ΔGAL5.1 and one ho-
mozygous ΔECR1) using a combination of predictive bioinformatics to
identify possible off-target sites, PCR to allow ampliﬁcation and isola-
tion of these sequences and Sanger sequencing and bioinformatics anal-
ysis to identify off-target effects in these sites.We analysed the effects of
CAS9 on the four most likely off-target cut sites of four different gRNAs
in three different foundermouse lines (both heterozygous and homozy-
gous ΔGAL5.1 and one ΔECR1; Fig. 1) to test the hypothesis that, if off-
target cutting by CAS9/CRISPR was to be an issue in our analyses, that
one or more of these predicted off-target sites would show evidence
of deletions, insertions or base pair changes characteristic of targeted
double strand cuts and subsequent non-homologous end joining repair
mechanisms. Using these approaches we were unable to provide any
evidence of off-target effects in the genomes of any of the three CAS9/
CRISPR enhancer deletion founder mouse lines generated using cyto-
plasmic injection of gRNA and CAS9 mRNA into 1-cell embryos.
It was reported that up to ﬁve mis-matches are tolerated by CAS9 in
the gRNA sequence to potentially cut at hundreds of alternative sites
across the genome (Fu et al., 2013; Mali et al., 2013). However, it is im-
portant to note that, in all of these studies, the off-target effects caused
by the CAS9/CRISPR systemoccurred in the genomes of transformed cell
lines transfected with plasmid-DNA constructs constitutively express-
ing gRNA and CAS9 protein (Fu et al., 2013; Mali et al., 2013; Jamal et
al., 2015). It is not surprising that exposing the genomes of rapidly di-
viding transfected cell lines to high levels of CAS9 and gRNA molecules
throughmultiple generationswould increase the incidence of off-target
effects in these cells. Indeed, the effects of increased levels of CAS9 activ-
ity was noted by Lin et al. (2015)who described that controlling the ex-
pression of CAS9 gRNA expressing plasmids produced signiﬁcantly less
off-target effects (Lin et al., 2015). In contrast to observations of off-tar-
get effects in cell lines, studies of the use of CAS9/CRISPR in the genera-
tion of transgenic mice have reported that off-target effects are far less
of an issue than those observed in cell lines (Shen et al., 2014; Chu et
al., 2016). Taken together with the results of the current study, that
has been unable to detect any evidence of off-target effects, we are con-
ﬁdent that, although the chances of off target events are still present, the
dangers of off-target site cutting by the CAS9 enzymewhen co-injected
as mRNA with gRNA are greatly exaggerated and do not constitute any
more of a risk than that encountered using ES cell targeting approaches
to deleting genome sequences.
From these and other studies it is clear that CRISPR/CAS9 technology
for deleting speciﬁc sequences from the genome will revolutionise our
understanding of the genome and its role in health and disease thanks
to the availability of the whole genome sequence of hundreds of verte-
brate genomes and the ease and speed of CAS9/CRISPR genome editing.
Although CRISPR/CA9 mediated sequence deletion is rapid and highly
efﬁcient, the introduction or alteration of sequences within the mouse
genome using 1-cell embryos still remains a challenge. This is because
these approaches require the co-injection of a DNA “repair template”
designed to trigger the homologous end joining repair pathway in the
cell to introduce targeted insertions or mutations. There may be several
reasonswhy this approach is less effective that the deletionmethod de-
scribed in the current study. The ﬁrst is that, because of its relative tox-
icity compared to RNA, DNA decreases the viability of 1-cell embryos
following microinjection. Secondly, it is essential that the repair tem-
plate be injected into the pronucleus of the 1-cell mouse embryo
which is trickier than microinjecting into the cytoplasm and results in
reduced embryo viability. Thirdly, because of the perceived problem ofPlease cite this article as: Hay, E.A., et al., An analysis of possible off target e
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the mRNA of the mutated “nickase” version of CAS9 that only cuts one
strand of the DNA target site thus only inducing the homologous repair
pathways within the cell. However, the nickase enzyme is nearly an
order of magnitude less efﬁcient than the wild type CAS9 protein. One
of the most important challenges that must be addressed when
attempting to produce subtle mutations using CRISPR technology is
that the injection of repair template, that involves the introduction of
a glass needle into the pronucleus of the embryo, does not compromise
the integrity of the embryo genome and only produces the designed
outcome. If this integrity could be assured and the efﬁciency of homol-
ogy directed repair increased, then the future for biology and CRISPR ge-
nome editing will be extremely bright.
5. Conclusions
Despite these problems the use of targeted genome deletions using
CAS9/CRISPR technologies is tremendously exciting and promises to
revolutionise our understanding of the role of tissue speciﬁc enhancers
in the cell speciﬁc regulation of neuropeptides and their receptors. We
have used comparative genomics to rapidly identify highly conserved
tissue speciﬁc enhancers of genes encoding neuropeptides that often
lie at considerable distances from the start sites of these genes. Being
able to delete these enhancers from the mouse genome using CAS9/
CRISPR technology allows us to span the huge gap between in-vitro
analysis of these enhancers (cell lines and transgenic reporter mice)
and allows us, for the ﬁrst time, to understand the role of these en-
hancers in-vivo. This novel ability will revolutionise our understanding
of the regulation of neuropeptides and will permit a greater under-
standing of the roles of genetic and epigenetic variation in altering neu-
ropeptide gene regulation in health and disease.
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